SWV responds to results of MAPS Phase 3 research and clinical trials
Read the Latest news
5 May 2021
MDMA-assisted therapy Phase 3 trials in the US show 'very encouraging clinical outcomes'
SWV is delighted by the announcement from the Multidisciplinary Association for Psychedelic Studies (MAPS) in the US of the successful completion, and very encouraging clinical outcomes, of the Phase 3 research and clinical trials it is conducting into MDMA-assisted therapy.
The UK charity SWV was set up in 2012, to serve those who have suffered physical or psychological injury in the UK armed forces and work to deliver independence to veterans through ground-breaking physical and psychological care. Supported by NHS England, SWV are working with world-class researchers at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London to deliver the UK’s first MDMA-Assisted Psychotherapy trial committed to finding an effective treatment for the most severe Post Traumatic Stress Disorder (PTSD).
Gilly Norton, Founder and CEO of SWV, said, “These results are good news and we are delighted to see them. The results of this trial suggest that the treatment could not only help veterans, but also other sufferers of trauma, who have treatment-resistant PTSD. We hope this will be a real game-changer in this complex and difficult field, and that it can be used to treat our veterans in the future.”
It is estimated that between a third and a half of PTSD cases overall are resistant to established treatments and this breakthrough by MAPS is a significant step forward in finding a new and effective treatment.
For press enquiries please email: email@example.com